| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-03-10 | Merck KGaA, Merck Serono (Germany) Illumina (USA - CA) | next-generation sequencing-based oncology diagnostic for clinical trials of targeted cancer therapies | collaboration development |
Cancer - Oncolog | Collaboration agreement | |
| 2015-03-10 | Adaptimmune (UK) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-03-09 | Merck Serono (Germany) Opexa Therapeutics (USA) | Tcelna™ (imilecleucel-T) | multiple sclerosis | development |
Autoimmune diseases - Neurodegenerative diseases | Development agreement |
| 2015-03-09 | Morphosys (Germany) Emergent BioSolutions (USA - MD) | ES414/MOR209 | metastatic castration-resistant prostate cancer (mCRPC) | licensing |
Cancer - Oncology | Milestone |
| 2015-03-09 | Nordic Nanovector (Norway) | nomination |
Nomination | |||
| 2015-03-09 | Sucampo Pharmaceuticals (USA - MD) R-Tech Ueno (Japan) | unoprostone isopropyl | lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension, retinitis pigmentosa and geographic atrophy | licensing development commercialisation |
Ophtalmological diseases | Licensing agreement |
| 2015-03-09 | Exact Sciences (USA - WI) Ironwood Pharmaceuticals (USA - MA) | Cologuard® (colorectal cancer screening test) | colorectal cancer | promotion |
Cancer - Oncology - Diagnostic | Establishment of a new subsidiary in the EU |
| 2015-03-07 | Sumitomo Dainippon Pharma (Japan) Takeda Pharmaceutical (Japan) | Latuda® (lurasidone) | schizophrenia, bipolar disorder | termination of an agreement |
CNS diseases - Mental diseases | Termination of the agreement |
| 2015-03-06 | Cellectis (France) ModiQuest Research (The Netherlands) | monoclonal antibodies | collaboration |
Technology - Services | Collaboration agreement | |
| 2015-03-05 | Adocia (France) | establishment of a new subsidiary in the US |
Metabolic diseases | Establishment of a new subsidiary in the US | ||
| 2015-03-05 | Inflectis Bioscience (France) Valneva (France) | 3D-Screen technology | licensing |
Technology - Services | Licensing agreement | |
| 2015-03-05 | SpePharm (The Netherlands), affiliate of Norgine (The Netherlands) Navidea Biopharmaceuticals (USA - OH) | Lymphoseek® (technetium Tc 99m tilmanocept) | imaging and intraoperative detection of sentinel lymph nodes in patients with melanoma, breast cancer or localized squamous cell carcinoma of the oral cavity | commercialisation distribution |
Cancer - Oncology - Diagnostic | Commercialisation agreement |
| 2015-03-05 | Thrombogenics (Belgium) | nomination |
Ophtalmological diseases | Nomination | ||
| 2015-03-04 | arGEN-X (The Netherlands - Belgium) de Duve Institute/UCL (Belgium) | antibody drug candidates - ARGX-115 | R&D |
Cancer - Oncology | Exercise of an option agreement | |
| 2015-03-04 | Sygnis (Germany) Funakoshi (Japan) | TruePrime™ | distribution |
Technology - Services | Distribution agreement | |
| 2015-03-04 | BMS (USA - NY) Bavarian Nordic (Denmark) | Prostvac® | asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) | licensing commercialisation |
Cancer - Oncology | Licensing agreement |
| 2015-03-04 | Eisai (Japan) Merck&Co (USA - NJ) | Keytruda® (pembrolizumab), Lenvima® (lenvatinib) and Halaven® (eribulin) | metastatic triple-negative breast cancer | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-03-04 | Checkpoint Therapeutics (USA - NY) TG Therapeutics (USA - NY) | anti-PD-L1 and anti-GITR antibody research programs | hematological malignancies | development commercialisation |
Cancer - Oncology | Development agreement |
| 2015-03-04 | Spectrum Pharmaceuticals (USA - NV) Hanmi Pharmaceuticals (South Korea) | poziotinib (HM781-36B) | licensing |
Cancer - Oncology | Licensing agreement | |
| 2015-03-04 | Adaptimmune (UK) | nomination |
Cancer - Oncology | Nomination |
